EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Ronald F van Vollenhoven, Li Wang, Joan T Merrill, Yi Liu, Chunde Bao, Fen Li, Jiankang Hu, Chenghui Huang, Jianhong Zhao, Cibo Huang, Hanyou Mo, Wei Wei und 11 weitere

New England Journal of Medicine · 16.10.2025 · 393 (15) · 1475-1485

DOI: 10.1056/nejmoa2414719 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.10.2025. Verfasst von Ronald F van Vollenhoven und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Amsterdam University Medical Center and Amsterdam Rheumatology Center, Amsterdam. Hauptthemen laut MEDLINE: B-Cell Activating Factor, Lupus Erythematosus, Systemic, Recombinant Fusion Proteins, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: RemeGen Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-Cell Activating FactorLupus Erythematosus, SystemicRecombinant Fusion ProteinsTumor Necrosis Factor Ligand Superfamily Member 13AdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodDrug Therapy, CombinationInjection Site ReactionInjections, SubcutaneousSeverity of Illness IndexRespiratory Tract InfectionsIncidenceTreatment OutcomeImmunoglobulins

Substanzen

B-Cell Activating FactorRecombinant Fusion ProteinstelitaciceptTumor Necrosis Factor Ligand Superfamily Member 13Immunoglobulins

Autor:innen und Institutionen

  • Department of Rheumatology, Amsterdam University Medical Center and Amsterdam Rheumatology Center, Amsterdam.
  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immuno…
  • Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City.
  • West China Hospital of Sichuan University, Chengdu, China.
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai.
  • Second Xiangya Hospital of Central South University, Changsha, China.

Förderung

  • RemeGen Co., Ltd

Zitieren

APA

van Vollenhoven, R. F., Wang, L., Merrill, J. T., Liu, Y., Bao, C., Li, F., Hu, J., Huang, C., Zhao, J., Huang, C., Mo, H., Wei, W., Lu, F., Li, J., Zhao, D., Wang, W., Li, L., Zuraw, Q., Wang, X., …, & 18C010 Trial Investigators (2025). A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. New England Journal of Medicine, 393(15), 1475-1485. https://doi.org/10.1056/nejmoa2414719

Vancouver

van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, et al. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. New England Journal of Medicine. 2025;393(15):1475-1485. doi:10.1056/nejmoa2414719

BibTeX
@article{vanVollenhoven2025,
  author = {van Vollenhoven, Ronald F and Wang, Li and Merrill, Joan T and Liu, Yi and Bao, Chunde and Li, Fen and Hu, Jiankang and Huang, Chenghui and Zhao, Jianhong and Huang, Cibo and Mo, Hanyou and Wei, Wei and Lu, Fu'ai and Li, Jingyang and Zhao, Dongbao and Wang, Wenxiang and Li, Lin and Zuraw, Qing and Wang, Xiaofei and Wang, Xuebin and Fang, Jianmin and Zhang, Fengchun and 18C010 Trial Investigators, 18C010 Trial Investigators},
  title = {A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {15},
  pages = {1475--1485},
  doi = {10.1056/nejmoa2414719}
}
Kostenlos starten →